Dianthus Therapeutics, Inc.

The runway holds up: revenue is set to grow 221%/yr over five years.10/10

Revenue is set to shrink 5%/yr over the next 3 years, a little behind the market.4/10

Revenue fell 32%/yr over the last 3 years, and it is still set to shrink 5%/yr.

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue fell 32%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

Growth is a weak point here: a business whose decline is easing. The one thing to watch: the company is not profitable yet.

Magnificent long-term results. Long-term holders have seen +606% over three years and +676% over five, ahead of 90% of the market.

It's up 146% over the past year, but 28% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+107%).

None flagged.

The stock is underperforming over the past month (-21%) and over three months (-11%).

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the stock is underperforming over the past month and over three months.